Response To: GCP III is Not the "off-target" for Urea-based PSMA-ligands

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2023 Jun 21

PMID 37341746

Authors

Gabriele Bassi

Samuele Cazzamalli

Sebastian Oehler

Laura Lucaroni

Tony Georgiev

Nicholas Favalli

Dario Neri

Affiliations

Soon will be listed here.

Citing Articles

A novel PSMA-targeting tracer with highly negatively charged linker demonstrates decreased salivary gland uptake in mice compared to [Ga]Ga-PSMA-11.

Huang S, DiFilippo F, Lindner D, Heston W EJNMMI Radiopharm Chem. 2024; 9(1):7.

PMID: 38289450 PMC: 10828251. DOI: 10.1186/s41181-024-00237-3.

References

Lucaroni L, Georgiev T, Prodi E, Puglioli S, Pellegrino C, Favalli N . Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics. Eur J Nucl Med Mol Imaging. 2022; 50(3):957-961. DOI: 10.1007/s00259-022-05982-8. View

Tykvart J, Schimer J, Jancarik A, Barinkova J, Navratil V, Starkova J . Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II. J Med Chem. 2015; 58(10):4357-63. DOI: 10.1021/acs.jmedchem.5b00278. View

Krall N, Pretto F, Mattarella M, Muller C, Neri D . A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo. J Nucl Med. 2016; 57(6):943-9. DOI: 10.2967/jnumed.115.170514. View

Millul J, Bassi G, Mock J, Elsayed A, Pellegrino C, Zana A . An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications. Proc Natl Acad Sci U S A. 2021; 118(16). PMC: 8072232. DOI: 10.1073/pnas.2101852118. View

Srinivasarao M, Galliford C, Low P . Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov. 2015; 14(3):203-19. DOI: 10.1038/nrd4519. View

Merkx R, Lobeek D, Konijnenberg M, Jimenez-Franco L, Kluge A, Oosterwijk E . Phase I study to assess safety, biodistribution and radiation dosimetry for Zr-girentuximab in patients with renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021; 48(10):3277-3285. PMC: 8426244. DOI: 10.1007/s00259-021-05271-w. View

Kulterer O, Pfaff S, Wadsak W, Garstka N, Remzi M, Vraka C . A Microdosing Study with Tc-PHC-102 for the SPECT/CT Imaging of Primary and Metastatic Lesions in Renal Cell Carcinoma Patients. J Nucl Med. 2020; 62(3):360-365. PMC: 8049338. DOI: 10.2967/jnumed.120.245530. View

Pandit-Taskar N, ODonoghue J, Divgi C, Wills E, Schwartz L, Gonen M . Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015; 5:28. PMC: 4425739. DOI: 10.1186/s13550-015-0104-4. View

Weich A, Serfling S, Yi H, Buck A, Higuchi T, Werner R . Complete Remission Upon Peptide Receptor Radionuclide Therapy in a G2 Pancreatic Neuroendocrine Tumor. Clin Nucl Med. 2023; 48(4):335-336. DOI: 10.1097/RLU.0000000000004537. View

10.

Tonnesmann R, Meyer P, Eder M, Baranski A . [Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative Autoradiography. Pharmaceuticals (Basel). 2019; 12(1). PMC: 6469177. DOI: 10.3390/ph12010018. View

11.

Rupp N, Umbricht C, Pizzuto D, Lenggenhager D, Topfer A, Muller J . First Clinicopathologic Evidence of a Non-PSMA-Related Uptake Mechanism for Ga-PSMA-11 in Salivary Glands. J Nucl Med. 2019; 60(9):1270-1276. DOI: 10.2967/jnumed.118.222307. View

12.

Ruigrok E, van Vliet N, Dalm S, de Blois E, van Gent D, Haeck J . Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020; 48(5):1339-1350. PMC: 8113296. DOI: 10.1007/s00259-020-05057-6. View